Welcome to our dedicated page for Genelux news (Ticker: GNLX), a resource for investors and traders seeking the latest updates and insights on Genelux stock.
Genelux Corp (GNLX) is a clinical-stage biopharmaceutical company pioneering oncolytic viral immunotherapies for aggressive solid tumors. This page serves as the definitive source for official news, press releases, and scientific developments related to GNLX’s innovative pipeline and proprietary CHOICE™ platform.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Content spans product development breakthroughs, peer-reviewed study outcomes, and operational announcements – all curated to support informed decision-making in the immuno-oncology sector.
Key updates include advancements in lead candidate Olvi-Vec’s clinical evaluation, platform technology enhancements, and analyses of treatment mechanisms for resistant cancers. All materials maintain compliance with financial disclosure standards while emphasizing therapeutic potential and scientific rigor.
Bookmark this page for streamlined access to verified GNLX developments. For real-time alerts on new announcements, consider subscribing to Stock Titan’s regulatory update service.
Genelux (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in BTIG's Virtual Biotechnology Conference 2024. The company's President, CEO, and Chairman, Thomas Zindrick, will engage in a fireside chat with Kaveri Pohlman, PhD, Director and BTIG Biotechnology Analyst. The discussion is scheduled for Tuesday, August 6, 2024, at 12:00 p.m. ET.
During the chat, Zindrick will provide insights into Genelux's clinical-stage programs, recent announcements, and upcoming milestones. This event presents an opportunity for investors and industry professionals to gain valuable information about Genelux's progress and future plans in the immuno-oncology field.
Genelux (Nasdaq: GNLX), an immuno-oncology company, has announced the pricing of an underwritten offering of 6,875,000 shares of common stock and accompanying warrants at $4.00 per share and warrant. Each warrant will have an exercise price of $5.25. The gross proceeds are expected to be approximately $27.5 million, with net proceeds providing working capital into Q1 2026. The funds will support the clinical development of Olvi-Vec, with Phase 3 trial results anticipated in H2 2025. The offering is expected to close around May 29, 2024. Guggenheim Securities and Newbridge Securities are managing the offering. A 30-day option for an additional 1,031,250 shares and warrants is also included.
Genelux (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, has announced a proposed public offering of its common stock and accompanying warrants. This offering is underwritten, with Guggenheim Securities acting as the sole book-running manager and Newbridge Securities as the co-manager. Genelux plans to grant underwriters a 30-day option to purchase an additional 15% of the shares sold.
The offering is backed by an effective shelf registration statement filed with the SEC, and a preliminary prospectus supplement will be filed. The completion of the offering is subject to market conditions and other customary closing conditions.
Genelux reported its first-quarter 2024 financial results and provided updates on its business activities. The company is progressing with its pivotal Phase 3 registration trial of Olvi-Vec in platinum resistant/refractory ovarian cancer and plans to expand its use into other cancer indications. Genelux is also enrolling patients in clinical trials for non-small cell lung cancer and recurrent small cell lung cancer. The company filed a shelf registration statement to offer up to $300.0 million in common stock, preferred stock, debt securities, and warrants. Financially, Genelux had $19.6 million in cash, cash equivalents, and short-term investments as of March 31, 2024. Research and development expenses increased by $1.2 million year-over-year, while general and administrative expenses increased by $0.3 million in the first quarter of 2024.
FAQ
What is the current stock price of Genelux (GNLX)?
What is the market cap of Genelux (GNLX)?
